
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is supported by broad-based U.S. strength, with Q3 revenue of $154.5M up 15.1% constant currency, led by Open Ablation and Pain Management growth of 17% and nearly 35%, while gross margin expanded to 77.3% and adjusted EBITDA nearly reached $27M. The company also raised 2026 guidance to $606M-$610M of sales and $91M-$94M of EBITDA, reflecting durable demand across its core franchises and improving operating leverage as clinicians adopt its therapies. Beyond the current quarter, the BoxX-NoAF trial is approaching full enrollment with a Spring ’27 readout expected, and management’s view that adjusted EBITDA could triple over three years underscores a compelling long-term fundamental backdrop.
Bears say
AtriCure is exposed to several concentrated execution risks, as disappointing sales from EPi-Sense/Convergent, softer-than-expected Open Ablation and AtriClip demand, and margin pressure could all undermine growth and profitability. Its outlook is further challenged by competitive threats, particularly potential market share loss to Medtronic’s Penditure surgical LAA closure device, which could weaken its position in a core cardiac surgery category. Given that the company relies on a direct sales force and distributors and generates a majority of revenue in the United States, any product shortfall or pricing pressure in its key end markets could quickly filter through to financial performance.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AtriCure (ATRC) Forecast
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares